197 related articles for article (PubMed ID: 29216362)
1. A Herpes Simplex Virus (HSV)-2 Single-Cycle Candidate Vaccine Deleted in Glycoprotein D Protects Male Mice From Lethal Skin Challenge With Clinical Isolates of HSV-1 and HSV-2.
Burn C; Ramsey N; Garforth SJ; Almo S; Jacobs WR; Herold BC
J Infect Dis; 2018 Feb; 217(5):754-758. PubMed ID: 29216362
[TBL] [Abstract][Full Text] [Related]
2. A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus.
Ramsey NLM; Visciano M; Hunte R; Loh LN; Burn Aschner C; Jacobs WR; Herold BC
J Virol; 2020 Jun; 94(13):. PubMed ID: 32295919
[TBL] [Abstract][Full Text] [Related]
3. Single dose of glycoprotein K (gK)-deleted HSV-1 live-attenuated virus protects mice against lethal vaginal challenge with HSV-1 and HSV-2 and induces lasting T cell memory immune responses.
Iyer AV; Pahar B; Chouljenko VN; Walker JD; Stanfield B; Kousoulas KG
Virol J; 2013 Oct; 10():317. PubMed ID: 24165088
[TBL] [Abstract][Full Text] [Related]
4. Murine Model of Maternal Immunization Demonstrates Protective Role for Antibodies That Mediate Antibody-Dependent Cellular Cytotoxicity in Protecting Neonates From Herpes Simplex Virus Type 1 and Type 2.
Kao CM; Goymer J; Loh LN; Mahant A; Burn Aschner C; Herold BC
J Infect Dis; 2020 Feb; 221(5):729-738. PubMed ID: 31599942
[TBL] [Abstract][Full Text] [Related]
5. A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.
Wang K; Goodman KN; Li DY; Raffeld M; Chavez M; Cohen JI
J Virol; 2016 Jan; 90(1):562-74. PubMed ID: 26559846
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
7. Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.
Çuburu N; Wang K; Goodman KN; Pang YY; Thompson CD; Lowy DR; Cohen JI; Schiller JT
J Virol; 2015 Jan; 89(1):83-96. PubMed ID: 25320297
[TBL] [Abstract][Full Text] [Related]
8. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.
Awasthi S; Huang J; Shaw C; Friedman HM
J Virol; 2014 Aug; 88(15):8421-32. PubMed ID: 24829358
[TBL] [Abstract][Full Text] [Related]
9. An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model.
Bagley KC; Schwartz JA; Andersen H; Eldridge JH; Xu R; Ota-Setlik A; Geltz JJ; Halford WP; Fouts TR
Viral Immunol; 2017 Apr; 30(3):178-195. PubMed ID: 28085634
[TBL] [Abstract][Full Text] [Related]
10. An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection.
Egan KP; Hook LM; Naughton A; Pardi N; Awasthi S; Cohen GH; Weissman D; Friedman HM
PLoS Pathog; 2020 Jul; 16(7):e1008795. PubMed ID: 32716975
[TBL] [Abstract][Full Text] [Related]
11. Design and evaluation of a multi-epitope assembly peptide (MEAP) against herpes simplex virus type 2 infection in BALB/c mice.
Wang X; Xie G; Liao J; Yin D; Guan W; Pan M; Li J; Li Y
Virol J; 2011 May; 8():232. PubMed ID: 21575169
[TBL] [Abstract][Full Text] [Related]
12. Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus.
Diaz FM; Knipe DM
Virology; 2016 Jan; 488():61-7. PubMed ID: 26609935
[TBL] [Abstract][Full Text] [Related]
13. Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models.
Khodai T; Chappell D; Christy C; Cockle P; Eyles J; Hammond D; Gore K; McCluskie MJ; Evans DM; Lang S; Loudon PT; Townend T; Wright P; West K; Bright H
Clin Vaccine Immunol; 2011 Oct; 18(10):1702-9. PubMed ID: 21852545
[TBL] [Abstract][Full Text] [Related]
14. Intramuscular Immunization of Mice with the Live-Attenuated Herpes Simplex Virus 1 Vaccine Strain VC2 Expressing Equine Herpesvirus 1 (EHV-1) Glycoprotein D Generates Anti-EHV-1 Immune Responses in Mice.
Liu SA; Stanfield BA; Chouljenko VN; Naidu S; Langohr I; Del Piero F; Ferracone J; Roy AA; Kousoulas KG
J Virol; 2017 Jun; 91(12):. PubMed ID: 28404844
[TBL] [Abstract][Full Text] [Related]
15. Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.
Davido DJ; Tu EM; Wang H; Korom M; Gazquez Casals A; Reddy PJ; Mostafa HH; Combs B; Haenchen SD; Morrison LA
J Virol; 2018 Sep; 92(17):. PubMed ID: 29950407
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model.
Delagrave S; Hernandez H; Zhou C; Hamberger JF; Mundle ST; Catalan J; Baloglu S; Anderson SF; DiNapoli JM; Londoño-Hayes P; Parrington M; Almond J; Kleanthous H
PLoS One; 2012; 7(10):e46714. PubMed ID: 23071620
[TBL] [Abstract][Full Text] [Related]
17. A recombinant herpes virus expressing influenza hemagglutinin confers protection and induces antibody-dependent cellular cytotoxicity.
Kaugars K; Dardick J; de Oliveira AP; Weiss KA; Lukose R; Kim J; Leung L; Rajagopalan S; Wolin S; Akabas L; Knipe DM; Bajic G; Jacobs WR
Proc Natl Acad Sci U S A; 2021 Aug; 118(34):. PubMed ID: 34417304
[TBL] [Abstract][Full Text] [Related]
18. Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease.
Petro C; González PA; Cheshenko N; Jandl T; Khajoueinejad N; Bénard A; Sengupta M; Herold BC; Jacobs WR
Elife; 2015 Mar; 4():. PubMed ID: 25756612
[TBL] [Abstract][Full Text] [Related]
19. A Novel High-Intensity Focused Ultrasound-Treated Herpes Simplex Virus 2 Vaccine Induces Long-Term Protective Immunity against Lethal Challenge in Mice.
Xiao J; Zhou X; Luo Y; Wang S; Yang Z; Yi Y; Xiong H
mSphere; 2020 Dec; 5(6):. PubMed ID: 33361122
[TBL] [Abstract][Full Text] [Related]
20. Vaccination of mice with herpes simplex virus type 1 glycoprotein D DNA produces low levels of protection against lethal HSV-1 challenge.
Ghiasi H; Cai S; Slanina S; Nesburn AB; Wechsler SL
Antiviral Res; 1995 Oct; 28(2):147-57. PubMed ID: 8585768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
